secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2022-05-05T23:59:59+00:00
Accession:  0001193125-22-141341
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AlloVir Q1 net loss $43.9M; advances posoleucel to Phase 3 multi-virus prevention
--------------------------------------------------------------------------------

- Net loss $43.9M ($0.69/share) vs $30.9M ($0.50) in Q1 2021; R&D spend $29.1M.
- Cash, equivalents & marketable securities $201.4M, down from $248.1M at year-end 2021.
- Initiated global Phase 3 registrational study of posoleucel to prevent 6 viruses in allo-HCT patients.
- FDA granted third RMAT designation for posoleucel multi-virus prevention; estimated addressable population 40,000 patients/year.
- FY2022 operating expense guidance reaffirmed at $130M–$145M excluding stock-based compensation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312522141341/0001193125-22-141341-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312522141341/d339026d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-141341

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer